194 related articles for article (PubMed ID: 24692738)
1. Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients.
Salem AH; Yang J; Graham A; Patnaik A; Holen K; Pradhan R; Xiong H
Anticancer Res; 2014 Apr; 34(4):2001-6. PubMed ID: 24692738
[TBL] [Abstract][Full Text] [Related]
2. Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer.
Yang J; Pradhan RS; Rosen LS; Graham AM; Holen KD; Xiong H
J Clin Pharm Ther; 2014 Dec; 39(6):680-4. PubMed ID: 25047139
[TBL] [Abstract][Full Text] [Related]
3. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.
Agarwal SK; Salem AH; Danilov AV; Hu B; Puvvada S; Gutierrez M; Chien D; Lewis LD; Wong SL
Br J Clin Pharmacol; 2017 Apr; 83(4):846-854. PubMed ID: 27859472
[TBL] [Abstract][Full Text] [Related]
4. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Kirschbrown W; Holen KD; Rosen LS
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1025-32. PubMed ID: 26420235
[TBL] [Abstract][Full Text] [Related]
5. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.
Wilson WH; O'Connor OA; Czuczman MS; LaCasce AS; Gerecitano JF; Leonard JP; Tulpule A; Dunleavy K; Xiong H; Chiu YL; Cui Y; Busman T; Elmore SW; Rosenberg SH; Krivoshik AP; Enschede SH; Humerickhouse RA
Lancet Oncol; 2010 Dec; 11(12):1149-59. PubMed ID: 21094089
[TBL] [Abstract][Full Text] [Related]
6. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
[TBL] [Abstract][Full Text] [Related]
7. Two-way interaction study between ritonavir boosted danoprevir, a potent HCV protease inhibitor, and ketoconazole in healthy subjects.
Morcos PN; Chang L; Navarro M; Chung D; Smith PF; Brennan BJ; Tran JQ
Int J Clin Pharmacol Ther; 2014 Feb; 52(2):103-11. PubMed ID: 24290411
[TBL] [Abstract][Full Text] [Related]
8. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Waring JF; Yang J; Holen KD; Rosen LS
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1041-9. PubMed ID: 26429709
[TBL] [Abstract][Full Text] [Related]
9. The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus.
Stroh M; Palcza J; McCrea J; Marsilio S; Breidinger S; Panebianco D; Johnson-Levonas A; Kraft WK; Orford K; Murphy G; Agrawal N; Trucksis M; Wagner JA; Iwamoto M
Cancer Chemother Pharmacol; 2012 May; 69(5):1247-53. PubMed ID: 22290273
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel.
Sarantopoulos J; Mita AC; Wade JL; Morris JC; Rixe O; Mita MM; Dedieu JF; Wack C; Kassalow L; Lockhart AC
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1113-24. PubMed ID: 25307552
[TBL] [Abstract][Full Text] [Related]
11. Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist.
Johnson BM; Adams LM; Zhang K; Gainer SD; Kirby LC; Blum RA; Apseloff G; Morrison RA; Schutz RA; Lebowitz PF
J Clin Pharmacol; 2010 Aug; 50(8):951-9. PubMed ID: 20124517
[TBL] [Abstract][Full Text] [Related]
12. Studying navitoclax, a targeted anticancer drug, in healthy volunteers--ethical considerations and risk/benefit assessments and management.
Xiong H; Pradhan RS; Nada A; Krivoshik AP; Holen KD; Rhodes JW; Gordon GB; Humerickhouse R; Awni WM
Anticancer Res; 2014 Jul; 34(7):3739-46. PubMed ID: 24982396
[TBL] [Abstract][Full Text] [Related]
13. Effect of ketoconazole on lobeglitazone pharmacokinetics in Korean volunteers.
Sil Oh E; Ok Kim C; Kim KH; Kim YN; Kim C; Lee JI; Park MS
Clin Ther; 2014 Jul; 36(7):1064-71. PubMed ID: 25047497
[TBL] [Abstract][Full Text] [Related]
14. The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199.
Choo EF; Boggs J; Zhu C; Lubach JW; Catron ND; Jenkins G; Souers AJ; Voorman R
Drug Metab Dispos; 2014 Feb; 42(2):207-12. PubMed ID: 24212376
[TBL] [Abstract][Full Text] [Related]
15. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
[TBL] [Abstract][Full Text] [Related]
16. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia.
Kaefer A; Yang J; Noertersheuser P; Mensing S; Humerickhouse R; Awni W; Xiong H
Cancer Chemother Pharmacol; 2014 Sep; 74(3):593-602. PubMed ID: 25053389
[TBL] [Abstract][Full Text] [Related]
17. A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.
Halama B; Hohmann N; Burhenne J; Weiss J; Mikus G; Haefeli WE
Clin Pharmacol Ther; 2013 Jun; 93(6):564-71. PubMed ID: 23511711
[TBL] [Abstract][Full Text] [Related]
18. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects.
Abbas R; Hug BA; Leister C; Burns J; Sonnichsen D
J Clin Pharmacol; 2011 Dec; 51(12):1721-7. PubMed ID: 21148045
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies.
Roberts AW; Advani RH; Kahl BS; Persky D; Sweetenham JW; Carney DA; Yang J; Busman TB; Enschede SH; Humerickhouse RA; Seymour JF
Br J Haematol; 2015 Sep; 170(5):669-78. PubMed ID: 25942994
[TBL] [Abstract][Full Text] [Related]
20. Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy white subjects in Germany.
Nakamaru Y; Hayashi Y; Sekine M; Kinoshita S; Thompson J; Kawaguchi A; Davies M; Jürgen Heuer H; Yamazaki H; Akimoto K
Clin Ther; 2014 May; 36(5):760-9. PubMed ID: 24726088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
